Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cresco Labs ( (TSE:CL) ) just unveiled an update.
Cresco Labs reported solid financial performance in Q2 2025, with a revenue of $164 million and a net loss of $14 million due to non-cash impairment charges. The company strengthened its financial position by securing a $325 million term loan, enhancing its balance sheet and providing financial flexibility for future growth opportunities. As the cannabis industry undergoes consolidation, Cresco Labs is positioned to capitalize on M&A opportunities with its proven operating model and clean capital structure.
The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.
Spark’s Take on TSE:CL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CL is a Neutral.
Cresco Labs’ overall score reflects a mixed outlook. The company’s strong cash flow and strategic market positioning are positive, but ongoing revenue challenges and high leverage weigh on the score. Technical indicators suggest some positive momentum, but valuation concerns persist due to negative earnings.
To see Spark’s full report on TSE:CL stock, click here.
More about Cresco Labs
Cresco Labs Inc. is a leading company in the cannabis industry, known for its branded cannabis products and Sunnyside dispensaries. It operates in multiple billion-dollar markets and focuses on maintaining a strong market share in a competitive environment.
Average Trading Volume: 372,592
Technical Sentiment Signal: Sell
Current Market Cap: C$432.8M
For a thorough assessment of CL stock, go to TipRanks’ Stock Analysis page.